In a move that underscores the high cost of poor quality in a pandemic, Emergent BioSolutions, Inc. is suspending production of COVID-19 vaccine drug substance in the midst of the race to reach herd immunity against the coronavirus and its emerging variants.
Emergent agreed to a request from the US Food and Drug Administration to suspend manufacturing operations and quarantine the drug substance for millions of doses made so far at its Bayview plant in